Losartan Potassium Tablet, Film Coated
Product Images NDC 71205-226

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71205-226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-226-30 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

Losartan Potassium 25 mg film-coated tablets packaging label from Proficient Rx LP. Contains 90 tablets, each with 25 mg of Losartan Potassium, USP. Tablets are white to off-white, round, with engraving 'S' on one side and '111' on the other. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd in China. Storage instructions included.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium, showing its molecular arrangement including rings, chlorine, hydroxymethyl groups, and potassium ion representation.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph compares the percentage of patients with the primary endpoint over 66 study months between Atenolol (dotted line) and Losartan Potassium (solid line). The chart notes an adjusted risk reduction of 13% with a p-value of 0.021, indicating a comparison of efficacy over time.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between Atenolol and Losartan Potassium. The x-axis represents study months, and the y-axis shows the percentage of affected patients. Losartan Potassium demonstrates a lower percentage compared to Atenolol, indicating an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' showing hazard ratios with 95% confidence intervals comparing Losartan Potassium and Atenolol. The figure includes event rates for primary composite and stroke outcomes across demographics such as age, gender, race, ISH, diabetes, and history of cardiovascular disease, with symbols proportional to sample sizes.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line chart showing the percentage of patients with an event over 48 months for Losartan Potassium versus Placebo. The graph compares these two groups, indicating a 16.1% risk reduction with Losartan Potassium, with significance noted by p=0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients experiencing the event.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.